SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (29046)7/8/1999 4:45:00 PM
From: Arthur Radley  Read Replies (1) | Respond to of 32384
 
From this job posting, it appears that LGND is still on the prowl.
"*Ligand Pharmaceuticals Inc.*

Ligand Pharmaceuticals is a specialty pharmaceutical company
transitioning to profitability following the launch of its first two
cancer drugs - with three NDA filings for additional products anticipated
this year. Associate Director/Director of Corporate Development whose
key responsibilities will include the identification and pursuit of
strategic product and/or company acquisition candidates, as well as the
establishment of creative new R&D ventures and strategic alliances.

biospace.com



To: bob zagorin who wrote (29046)7/12/1999 8:54:00 AM
From: jayhawk969  Read Replies (3) | Respond to of 32384
 
Bob,

From recall, the date is August 2nd, 6 months after Ontak's formal approval. Each share of Ontak is worth approximately $.23 per share in cash or Ligand stock at that time. A fairly significant dilution--therefore I expect good news from Ligand to help pump the stock for the base period preceding the 2nd of August.

J.D.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News